Merve Dede

3 weeks ago | nature.com | Hind Rafei |Rafet Basar |Sunil P Acharya |Vakul Mohanty |Ranjan Upadhyay |Merve Dede | +12 more

AbstractChimeric antigen receptor (CAR) natural killer (NK) cell immunotherapy offers a promising approach against cancer1,2,3. However, the molecular mechanisms that regulate CAR-NK cell activity remain unclear. Here we identify the transcription factor cyclic AMP response element modulator (CREM) as a crucial regulator of NK cell function.

Aug 22, 2024 | digitalcommons.library.tmc.edu | Yuefan Huang |Vakul Mohanty |Merve Dede |Kyle P. Tsai

AbstractCells often alter metabolic strategies under nutrient-deprived conditions to support their survival and growth. Characterizing metabolic reprogramming in the tumor microenvironment (TME) is of emerging importance in cancer research and patient care. However, recent technologies only measure a subset of metabolites and cannot provide in situ measurements.

Jan 18, 2024 | nature.com | Hind Rafei |May Daher |Vakul Mohanty |Merve Dede |Peter F Thall |Roland Bassett | +6 more

AbstractThere is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+ B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR).